Proje Geliştirme ve
Koordinasyon Birimi

2016-11-13 Romania: Genetic Events in Chronic Lymphocytic Leukemia Evolution

Genetic Events in Chronic Lymphocytic Leukemia Evolution

Description of the project offered: 

Aim of this study is to present the latest researches in the field of molecular medicine, in terms of Chronic Lymphocytic Leukemia (CLL), emerged from the P53 gene deletion in human lymphoma genome.
In recent years proved that the best technique in the investigation of malignant lymphocytes is the Fluorescence in situ hybridization (FISH). This method is used as an alternative to chromosomal banding, a conventional application in molecular medicine.
Previous results: 
In the literature it was registered, in previous years, on an international study, conducted on 109 cases of CLL, 79 cases (72.5%) who had more genetic abnormalities: the remaining 30 cases (27.5%) had normal results, using FISH technology. The majority of patients, 67% (53.79) had a single anomaly and the remaining 33% had two or three genetic abnormalities. The chromosomes 14q32 /17p translocations in LLC genome, which appeared similar to some common, had demonstrated abnormalities involving IGH gene, located on chromosome14q32. 
Recent, endogenous somatic gene therapy research is a basic of trial clinical and therapeutic trial.
The studies of genotypic and phenotypic chromosomes aberrations by FISH method allow the identification of differential diagnosis at patients with CCL. 
frequencies of gene mutations, deletions or translocations of P53, in CLL, can be classified as biomarkers of individual proteomic and genomic profile for this type of leukemia. 
Identification of P53 gene deletions and mutations in regions of chromosome 17 in hematological malignancies is important because these mutations have an impact on the clinical management of patients and requires an attitude adjustment therapeutic adequate in a personalized medicine.
Personalized treatments will be applied by combining diagnostic tools, knowledge databases and therapeutic drugs.
Project proposer:   Aurelian Udristioiu ()
Partner role:  Project participant 
Partner organisation:  Research
Call for proposal title:  CALL: FET-Open – Novel ideas for radically new technologies 
Call for proposal identifier:  H2020-FETOPEN-2016-2017

Description of the collaboration sought: 
Interests of doctors in all specialties, medical students , staff working in clinical laboratories based on the fact that this work rests on a solid scientific information , rigorously confronted with the author's own experience gained in basic medical education in the country and abroad.
This strategy could be particularly beneficial in treating cancers that do not harbor TP53 mutations. For example in hematologic malignancies, such as multiple myeloma, chronic lymphocytic leukemia (CLL).
Please, consult the following offer, on link : An interphase nucleus of normal human lymphocyte was stained with HER2/CEN17q FISH Probe, for about 100 cases. HER2/CEN17q FISH Probe; FG0006. 
Expertise sought: Scientific research, Project management methodologies, Medical biotechnology, Medicine. Health, 
Roles sought: Project participant, 
Organisation types sought: Research, 
Countries sought: Romania, Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, United Kingdom, Albania, Bosnia and Herzegovina, Croatia, Iceland, Israel, Liechtenstein, Macedonia, the former Yugoslav Republic of, Montenegro, Norway, Serbia, Switzerland, Turkey, 

Call for proposal specific information
The referenced call for proposals has no specific fields defined.